Eli Lilly and Company logo
Eli Lilly and Company (LLY)
Compare

Eli Lilly and Company (LLY) Shares Outstanding: 0.90

Is Eli Lilly and Company’s shares outstanding high or low?

Eli Lilly and Company's shares outstanding of 0.90 is in line with its 5-year average of 0.93, near the low end of its 5-year range (0.90–0.96).

0.14% below its 12-month average of 0.90.

LLY Shares Outstanding Chart

LLY Shares Outstanding
0.90-0.29% 1Y
Zoom

LLY Average Shares Outstanding Chart

LLY Current vs Average Shares Outstanding Chart

LLY Shares Outstanding Metrics

SHARES OUTSTANDING

0.90

SHARES OUTSTANDING AVG TTM

0.90

SHARES OUTSTANDING AVG 3Y

0.91

SHARES OUTSTANDING AVG 5Y

0.93

SHARES OUTSTANDING AVG 10Y

0.98

SHARES OUTSTANDING AVG 15Y

1.02

SHARES OUTSTANDING AVG 20Y

1.04

CURRENT VS TTM AVG

-0.14%

CURRENT VS 3Y AVG

-1.54%

CURRENT VS 5Y AVG

-3.07%

CURRENT VS 10Y AVG

-8.55%

CURRENT VS 15Y AVG

-12.37%

CURRENT VS 20Y AVG

-13.71%

Share Structure

Shares Outstanding

898.00M

Float Shares

N/A

Stock Price

$1136.37

Market Cap

$1095.8B

Annual Shares Outstanding History

YearWeighted Average SharesYoY Change
2025898.00M-0.29%
2024900.61M+0.14%
2023899.38M-5.35%
2022950.18M-0.36%
2021953.65M-0.31%
2020956.59M-0.10%
2019957.53M-6.83%
20181.03B-2.31%
20171.05B-4.44%
20161.10B-0.40%
20151.11B-0.48%
20141.11B-0.55%
20131.12B-2.59%
20121.15B+2.92%
20111.11B+0.74%
20101.11B+0.68%
20091.10B+0.35%
20081.09B+0.37%
20071.09B+0.33%
20061.09B-0.08%
20051.09B+0.35%
20041.08B+0.74%
20031.08B-0.27%
20021.08B+0.12%
20011.08B-0.28%
20001.08B-0.72%
19991.09B-0.78%
19981.10B-0.38%
19971.10B+0.68%
19961.09B-

Relationship: Market Cap = Shares Outstanding × Stock Price

Key concepts:

  • Float shares: Shares available for public trading
  • Dilution: When new shares are issued, existing shareholders own less
  • Buybacks: Reduce share count, increasing EPS and ownership stake
  • Stock splits: Increase share count but don't change market cap

Eli Lilly and Company Shares Outstanding Formula & Definition

Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Eli Lilly and Company Shares Outstanding FAQ

What is the shares outstanding for Eli Lilly and Company (LLY)?
The shares outstanding for LLY stock is 0.90.
Is Eli Lilly and Company's shares outstanding high or low?
Eli Lilly and Company's shares outstanding of 0.90 is in line with its 5-year average of 0.93, near the low end of its 5-year range (0.90–0.96).
What is the TTM average shares outstanding for Eli Lilly and Company (LLY)?
The TTM average shares outstanding for LLY stock is 0.90.
What is the 3Y average shares outstanding for Eli Lilly and Company (LLY)?
The 3Y average shares outstanding for LLY stock is 0.91.
What is the 5Y average shares outstanding for Eli Lilly and Company (LLY)?
The 5Y average shares outstanding for LLY stock is 0.93.
What is the 10Y average shares outstanding for Eli Lilly and Company (LLY)?
The 10Y average shares outstanding for LLY stock is 0.98.
What is the 15Y average shares outstanding for Eli Lilly and Company (LLY)?
The 15Y average shares outstanding for LLY stock is 1.02.
What is the 20Y average shares outstanding for Eli Lilly and Company (LLY)?
The 20Y average shares outstanding for LLY stock is 1.04.

Eli Lilly and Company Shares Outstanding History

DATESHARES OUTSTANDING
2025-12-310.90
2024-12-310.90
2023-12-310.90
2022-12-310.95
2021-12-310.95
2020-12-310.96
2019-12-310.96
2018-12-311.03
2017-12-311.05
2016-12-311.10
2015-12-311.11
2014-12-311.11
2013-12-311.12
2012-12-311.15
2011-12-311.11
2010-12-311.11
2009-12-311.10
2008-12-311.09
2007-12-311.09
2006-12-311.09
2005-12-311.09
2004-12-311.08
2003-12-311.08
2002-12-311.08
2001-12-311.08
2000-12-311.08
1999-12-311.09
1998-12-311.10
1997-12-311.10
1996-12-311.09

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Indianapolis, IN
47,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
David A. Ricks